The Parkinson’s disease-associated mutation LRRK2-G2019S impairs synaptic plasticity in mouse hippocampus

Journal of Neuroscience

Volumn 35, Issue 32, 2015, Pages 11190-11195

  Sweet, Eric S ^a   Saunier Rebori, Bernadette ^a   Yue, Zhenyu ^a   Blitzer, Robert D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Aged; Electrophysiology; Long term depression; LRRK2; Nonmotor deficits; Transgenic

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE MUTATION; GENE OVEREXPRESSION; HIPPOCAMPUS; LEUCINE RICH REPEAT KINASE 2 GENE; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION; WHOLE CELL PATCH CLAMP; AGE; ANIMAL; GENETICS; MUTATION; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; ANIMALS; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; MUTATION; NEURONAL PLASTICITY; PARKINSON DISEASE; PHENOTYPE; PROTEIN-SERINE-THREONINE KINASES; SYNAPTIC TRANSMISSION;

EID: 84939163201     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0040-15.2015     Document Type: Article

References (32)

1. Alcalay RN, Mirelman A, Saunders-Pullman R, Tang MX, Mejia Santana H, Raymond D, Roos E, Orbe-Reilly M, Gurevich T, Bar Shira A, Gana Weisz M, Yasinovsky K, Zalis M, Thaler A, Deik A, Barrett MJ, Cabassa J, Groves M, Hunt AL, Lubarr N et al. (2013) Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. Mov Disord 28:1966-1971. CrossRef Medline
2. Beccano-Kelly DA, Volta M, Munsie LN, Paschall SA, Tatarnikov I, Co K, Chou P, Cao LP, Bergeron S, Mitchell E, Han H, Melrose HL, Tapia L, Raymond LA, Farrer MJ, Milnerwood AJ (2015) LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 24:1336-1349. CrossRef Medline
3. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211. CrossRef Medline
4. Chou JS, Chen CY, Chen YL, Weng YH, Yeh TH, Lu CS, Chang YM, Wang HL (2014) (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse. Neurobiol Dis 68:190-199. CrossRef Medline
5. Cirnaru MD, Marte A, Belluzzi E, Russo I, Gabrielli M, Longo F, Arcuri L, Murru L, Bubacco L, Matteoli M, Fedele E, Sala C, Passafaro M, Morari M, Greggio E, Onofri F, Piccoli G (2014) LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex. Front Mol Neurosci 7:49. CrossRef Medline
6. Godena VK, Brookes-Hocking N, Moller A, Shaw G, Oswald M, Sancho RM, Miller CC, Whitworth AJ, De Vos KJ (2014) Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations. Nat Commun 5:5245. CrossRef Medline
7. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844. CrossRef Medline
8. Heo HY, Kim KS, Seol W (2010) Coordinate regulation of neurite outgrowth by LRRK2 and its interactor, Rab5. Exp Neurobiol 19:97–105. CrossRef Medline
9. Kandiah N, Zainal NH, Narasimhalu K, Chander RJ, Ng A, Mak E, Au WL, Sitoh YY, Nadkarni N, Tan LC (2014) Hippocampal volume and white matter disease in the prediction of dementia in Parkinson’s disease. Parkinsonism Relat Disord 20:1203–1208. CrossRef Medline
10. Kehagia AA, Barker RA, Robbins TW (2010) Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson’s disease. Lancet Neurol 9:1200-1213. CrossRef Medline
11. Law BM, Spain VA, Leinster VH, Chia R, Beilina A, Cho HJ, Taymans JM, Urban MK, Sancho RM, Blanca Ramírez M, Biskup S, Baekelandt V, Cai H, Cookson MR, Berwick DC, Harvey K (2014) A direct interaction between leucine-rich repeat kinase 2 and specific b-tubulin isoforms regulates tubulin acetylation. J Biol Chem 289:895–908. CrossRef Medline
12. Lee S, Liu HP, Lin WY, Guo H, Lu B (2010) LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci 30:16959-16969. CrossRef Medline
13. Leroi I, McDonald K, Pantula H, Harbishettar V (2012) Cognitive impairment in Parkinson disease: impact on quality of life, disability, and caregiver burden. J Geriatr Psychiatry Neurol 25:208-214. CrossRef Medline
14. Li X, Patel JC, Wang J, Avshalumov MV, Nicholson C, Buxbaum JD, Elder GA, Rice ME, Yue Z (2010) Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson’s disease mutation G2019S. J Neurosci 30:1788–1797. CrossRef Medline
15. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, MacCabe BD, Marder KS, Honig LS, Clark LN, Small SA, Abeliovich A (2013) RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson’s disease risk. Neuron 77:425–439. CrossRef Medline
16. Matta S, Van Kolen K, da Cunha R, van den Bogaart G, Mandemakers W, Miskiewicz K, De Bock PJ, Morais VA, Vilain S, Haddad D, Delbroek L, Swerts J, Chávez-Gutièrrez L, Esposito G, Daneels G, Karran E, Holt M, Gevaert K, Moechars DW, De Strooper B et al. (2012) LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 75: 1008–1021. CrossRef Medline
17. Morishita W, Marie H, Malenka RC (2005) Distinct triggering and expression mechanisms underlie LTD ofAMPAandNMDAsynaptic responses. Nat Neurosci 8:1043–1050. CrossRef Medline
18. Nagano-Saito A, Habak C, Mejía-Constaín B, Degroot C, Monetta L, Jubault T, Bedetti C, Lafontaine AL, Chouinard S, Soland V, Ptito A, Strafella AP, Monchi O (2014) Effect of mild cognitive impairment on the patterns of neural activity in early Parkinson’s disease. Neurobiol Aging 35:223–231. CrossRef Medline
19. Parisiadou L, Yu J, Sgobio C, Xie C, Liu G, Sun L, Gu XL, Lin X, Crowley NA, Lovinger DM, Cai H (2014) LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci 17:367–376. CrossRef Medline
20. Pereira JB, Junquè C, Bartrès-Faz D, Ramírez-Ruiz B, Marti MJ, Tolosa E (2013) Regional vulnerability of hippocampal subfields and memory deficits in Parkinson’s disease. Hippocampus 23:720-728. CrossRef Medline
21. Piccoli G, Condliffe SB, Bauer M, Giesert F, Boldt K, De Astis S, Meixner A, Sarioglu H, Vogt-Weisenhorn DM, Wurst W, Gloeckner CJ, Matteoli M, Sala C, Ueffing M (2011) LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 31:2225–2237. CrossRef Medline
22. Plowey ED, Johnson JW, Steer E, Zhu W, Eisenberg DA, Valentino NM, Liu YJ, Chu CT (2014) Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration. Biochim Biophys Acta 1842:1596-1603. CrossRef Medline
23. Rosahl TW, Spillane D, Missler M, Herz J, Selig DK, Wolff JR, Hammer RE, Malenka RC, Südhof TC (1995) Essential functions of synapsins I and II in synaptic vesicle regulation. Nature 375:488–493. CrossRef Medline
24. Sepulveda B, Mesias R, Li X, Yue Z, Benson DL (2013) Short- and long-term effects of LRRK2 on axon and dendrite growth. PLoS One 8:e61986. CrossRef Medline
25. Shanker V, Groves M, Heiman G, Palmese C, Saunders-Pullman R, Ozelius L, Raymond D, Bressman S (2011) Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson’s disease. Mov Disord 26:1875–1880. CrossRef Medline
26. Sheng Z, Zhang S, Bustos D, Kleinheinz T, Le Pichon CE, Dominguez SL, Sollanoy HO, Drummond J, Zhang X, Ding X, Cai F, Song Q, Li X, Yue Z, van der Brug MP, Burdick DJ, Gunzer Toste J, Chen H, Liu X, Estrada AA et al. (2012) Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations. Sci Transl Med 4:164ra164. CrossRef
27. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, Hatano T, Hattori N, Kim KS, Chang S, Seol W (2008) LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314:2055–2065. CrossRef Medline
28. Stafa K, Tsika E, Moser R, Musso A, Glauser L, Jones A, Biskup S, Xiong Y, Bandopadhyay R, Dawson VL, Dawson TM, Moore DJ (2014) Functional interaction of Parkinson’s disease-associated LRRK2 with members of the dynamin GTPase superfamily. HumMol Genet 23:2055–2077. CrossRef Medline
29. Taymans JM, Van den Haute C, Baekelandt V (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J Neurochem 98:951–961. CrossRef Medline
30. Wang X, Yan MH, Fujioka H, Liu J, Wilson-Delfosse A, Chen SG, Perry G, Casadesus G, Zhu X (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21:1931–1944. CrossRef Medline
31. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, Brayne C, Kolachana BS, Weinberger DR, Sawcer SJ, Barker RA (2009) The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 132:2958-2969. CrossRef Medline
32. Winner B, Melrose HL, Zhao C, Hinkle KM, Yue M, Kent C, Braithwaite AT, Ogholikhan S, Aigner R, Winkler J, Farrer MJ, Gage FH (2011) Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis 41:706-716. CrossRef Medline